Drug Trial Radar · NCT06602271
PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Dec 9, 2025
Primary completion
Aug 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Ensysce BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Rho, Inc.
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the analgesic activity of PF614 (an oral oxycodone prodrug extended-release analgesic) for control of postsurgical pain in subjects scheduled for abdominoplasty surgery. The main question to be answered is: • To assess the analgesic efficacy of PF614 compared to placebo in subjects with moderate to severe pain following abdominoplasty. Participants will be asked to take oral blinded doses of study medication at about one hour before surgery starts, and then every 12 hours after surgery for up to 4 days. Participants will be asked to: * Rate their pain on a 0-10 numerical rating scale (NRS) at various timepoints up to 5 days following surgery; * Tell us about the need for rescue medication if they continue to have moderate-to-severe pain; * Tell us about any side effects or adverse effects that they may experience to help us understand the safety and tolerability of the test medications; * Provide periodic blood samples to help us understand how much study drug is in their system. Participants will stay in a clinic setting and be monitored for safety for 5 days following surgery. We anticipate that participants will be discharged on Day 5, pending medical review, and then keep a diary to record study-related pain and adverse effects for an additional 2-4 days after discharge.
Conditions
- Postoperative Pain, Acute
Interventions
PF614 capsuleDrug
Experimental oxycodone prodrug
PlaceboDrug
Inactive medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain NRS-R area under the curve through 48 hours (AUC4-48)Time frame: 4-48 hours
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CenExel / Atlanta Center for Medical Research (ACMR)
Atlanta, Georgia · Recruiting
HD Research - Memorial Hermann Surgery Center
Houston, Texas · Recruiting
CenExel / JBR
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.